Shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) hit a new 52-week low during trading on Monday . The company traded as low as $6.04 and last traded at $6.41, with a volume of 366,025 shares. The stock had previously closed at $6.63.

TNDM has been the subject of a number of recent research reports. Piper Jaffray Cos. reissued a “buy” rating and set a $12.00 price objective on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Robert W. Baird reaffirmed a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, May 2nd. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a report on Wednesday, May 4th. Sterne Agee CRT reaffirmed a “neutral” rating on shares of Tandem Diabetes Care in a report on Monday, May 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Tandem Diabetes Care in a report on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Tandem Diabetes Care currently has a consensus rating of “Buy” and a consensus target price of $14.21.

The company’s 50-day moving average is $7.53 and its 200-day moving average is $8.19. The stock’s market cap is $195.62 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.05. The company earned $23 million during the quarter, compared to analysts’ expectations of $23.08 million. The business’s quarterly revenue was up 46.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) earnings per share. Analysts expect that Tandem Diabetes Care Inc. will post ($2.16) EPS for the current year.

An institutional investor recently raised its position in Tandem Diabetes Care stock. Westfield Capital Management Co. LP increased its stake in Tandem Diabetes Care Inc. (NASDAQ:TNDM) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,125,281 shares of the medical device company’s stock after buying an additional 35,680 shares during the period. Westfield Capital Management Co. LP owned 3.74% of Tandem Diabetes Care worth $13,290,000 as of its most recent SEC filing.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.